EUCTR2017-000329-11-DE进行中（未招募）1 期
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer - Elderly / AIO KRK 0117
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest0 个研究点目标入组 124 人开始时间: 2017年12月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.To enter this trial, the oncologist has to confirm that the reason for entering the trial was advanced age alone or age and frailty. As an operational definition for frailty the G8 screening tool will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an established screening tool that includes seven items from the Mini Nutritional Assessment (MNA) and an age-related item (<80, 80 to 85, or 85 years). The total score can range from 0 to 17. The result on the G8 is considered abnormal if the score is =14, indicating a geriatric risk profile.
- •Due to age or frailty, the patient might not be a candidate for standard full-dose combination therapy.
- •2.Patients have to have histologically confirmed mCRC with unidimensionally measurable inoperable metastatic disease
- •3.ECOG performance status of 2 or better.
- •4.Life expectancy of 3 months or longer at enrolment
- •5.Patients =70 years with no upper age limit
- •6.Previous adjuvant chemotherapy is allowed if completed more than 6 months before randomisation
- •7.Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before randomisation
- •8.Hematological status:
- •Neutrophils (ANC) = 1.5 x 109/L
- •Platelets = 100 x 109/L
- •Hemoglobin = 9 g/dL
- •9.Adequate renal function:
- •Serum creatinine level = 1.5 x upper limit normal (ULN)
- •10.Adequate liver function:
- •Serum bilirubin = 1.5 x upper limit normal (ULN)
- •Alkaline phosphatase = 2.5 x ULN (unless liver metastases are present, then < 5 x ULN in that case)
- •AST and ALT < 3 x ULN (unless liver metastases are present then < 5 x ULN in that case)
- •11.Proteinuria < 2+ (dipstick urinalysis) or = 2 g/24hour
- •12.Signed and dated informed consent, and willing and able to comply with protocol requirements
- •13.Regular follow-up feasible
- •14.Male patients with a partner of childbearing potential must agree to use effective contraception (Pearl Index < 1) during the course of the trial and at least 3 months after last administration of the study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 124
排除标准
- •1.Prior systemic chemotherapy for mCRC
- •2.Other concomitant or previous malignancy, except:
- •Adequately treated in-situ carcinoma of the uterine cervix
- •Basal or squamous cell carcinoma of the skin
- •Cancer in complete remission for >3 years
- •3.Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days before start of study treatment.
- •4.History or evidence upon physical examination of CNS metastasis unless adequately treated (irradiation and no seizure with appropriate treatment)
- •5.Uncontrolled hypercalcemia
- •6.Pre-existing peripheral neuropathy (NCI grade =2) resulting from previous therapy
- •7.Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
- •8.Treatment with any other investigational medicinal product within 28 days prior to study treatment.
- •9.Significant cardiovascular disease:
- •Cardiovascular accident or myocardial infarction or unstable angina =6 months before start of study treatment
- •Severe cardiac arrhythmia
- •New York Heart Association grade =2 congestive heart failure
- •Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy.
- •History of stroke or transient ischemic attack =6 months before start of study treatment
- •Coronary/peripheral artery bypass graft =6 months before start of study treatment.
- •Deep vein thrombosis or thromboembolic events =1 month before start of study treatment
- •10.Patients with known allergy to any excipient to study drugs,
- •11.Any of the following within 3 months prior to randomization: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
- •12.Bowel obstruction before start of study treatment.
- •13.Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization
- •14.Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •15.Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of sponsor and study site)
- •16.Patient who might be dependent on the sponsor, site or the investigator
- •17.Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- •18.Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
研究者
相似试验
已完成
2 期
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal CancerColorectal CancerNCT03530267Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest124
已完成
2 期
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal CancerRectal CancerNCT02340949Grupo Espanol Multidisciplinario del Cancer Digestivo180
进行中（未招募）
1 期
Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trialPatients with high risk locally advanced rectal carcinoma (defined by Magnetic Resonance Imaging [MRI]), who are candidates for multimodality treatment.MedDRA version: 17.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2014-002063-14-ESGEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo)180
已完成
不适用
FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility studyColorectal cancerJPRN-UMIN000003673niversity of Toyama20
已完成
4 期
Pilot study of FOLFOX or XELOX Therapy Versus FOLFOX or XELOX + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colon CancerColon cancerJPRN-UMIN000006134Tokai University School of Medicine20